Full-year core operating income was broadly flat at $16.7 billion, it said in a statement.
(Reporting by Ludwig Burger; Editing by Paul Carrel)
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
89.05 CHF | +0.20% | +1.93% | +4.93% |
12:54pm | Avacta picks Christina Coughlin to replace long-serving CEO | AN |
04-30 | FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications | MT |
BASEL (Reuters) - Swiss drugmaker Novartis on Wednesday predicted that core operating income would grow in a "mid single digit" percentage range in 2023, following stagnation last year.
Full-year core operating income was broadly flat at $16.7 billion, it said in a statement.
(Reporting by Ludwig Burger; Editing by Paul Carrel)
1st Jan change | Capi. | |
---|---|---|
+4.93% | 198B | |
+32.68% | 704B | |
+27.95% | 577B | |
-4.54% | 348B | |
+18.17% | 327B | |
+4.65% | 288B | |
+14.60% | 234B | |
-9.78% | 194B | |
-4.69% | 147B | |
-8.20% | 145B |